Pharmesis International

Pharmesis International, established in 1996, operates as a key player in the Pharmaceuticals and Healthcare industries, identified by its ticker SGX: BFK. The company is publicly listed on the Main Board of the Singapore Exchange, underscoring its commitment to transparency and robust corporate governance. Pharmesis International's core business encompasses the full spectrum of pharmaceutical product development, from initial research and development through to production and sales. Its diverse product offerings include both Western medicine and Traditional Chinese Medicine (TCM), addressing a wide array of health needs and therapeutic areas. The company is dedicated to advancing healthcare solutions through continuous innovation and a focus on quality.

Employing between 500 and 1,000 individuals across its 2 operational locations, Pharmesis International possesses substantial capacity for its market activities. The company markets its pharmaceutical products under established brands, notably Kinna and Longlife, which are distributed to approximately 2,000 hospitals throughout China. This extensive network signifies a strong market presence and effective distribution strategy. To gain insight into the individuals driving these operations, one can Meet Pharmesis International's team.

Pharmesis International generated a revenue of $38.7M. The company places significant emphasis on corporate social responsibility (CSR) and sustainable development, integrating these principles into its operational framework. Its overarching mission is to enhance the health and well-being of families globally by delivering innovative and accessible pharmaceutical products. The company's strategic direction is geared towards long-term growth and positive societal impact within the healthcare sector.